#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Fabry dis­ease, an overview and the most com­mon neurological manifestations


Authors: P. Reková 1;  K. Sedláková 2;  G. Dostálová 3;  A. Linhart 3
Authors place of work: Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze 1;  Oční klinika 1. LF UK a VFN v Praze 2;  II. interní klinika – klinika kardiologie a angiologie 1. LF UK a VFN v Praze 3
Published in the journal: Cesk Slov Neurol N 2018; 81(2): 156-163
Category: Přehledný referát
doi: https://doi.org/10.14735/amcsnn2018156

Snímky z MR jsou publikovány se svolením Radiologické kliniky 1. LF UK a VFN, za jejich poskytnutí autoři děkují. Za poskytnutí fotografie kožních angiokeratomů patří poděkování MU Dr. Lukáši Lacinovi, Ph.D., z Dermatovenerologické kliniky 1. LF UK a VFN

Summary

Fabry disease is a rare inherited lysosomal storage disorder. Patients with classical multisystemic disease have frequent neurological manifestations. It is of great importance for patients to be diagnosed early and properly since there is specific disease therapy available. This article provides an overview of current knowledge about Fabry disease with emphasis on its neurological manifestations.

Key words:
Fabry disease – small fi ber neuropathy – stroke – enzyme-replacement therapy

P. Reková has been in receipt of travel grant and honoraria for lectures on Fabry disease from Shire HGT and Sanofi Genzyme. K. Sedláková has been in receipt of honoraria for lectures on Fabry disease from Shire HGT. G. Dostálová has been in receipt of travel grants and honoraria for lecures on Fabry disease from Protalix Biotherapeutics, Shire HGT and Sanofi Genzyme. A. Linhart has been in receipt of travel grants and honoraria for lectures on Fabry disease from Shire HGT, Sanofi Genzyme and Amicus Therapeutics.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.


Zdroje

1. Germain DP. Fabry dis­ease. Orphanet J Rare Dis 2010; 5: 30. doi: 10.1186/ 1750-1172-5-30.

2. Anderson W. A case of angiokeratoma. BR J Dermatol 1898; 10: 113– 117.

3. Fabry J. Ein Beitrag zur Ken­ntnis der Purpura hae-morhagica nodularis (Purpura papulosa haemor­rhagica herbae). Arch Derm Syph 1898; 43: 187– 200.

4. Sweeley CC, Klionsky B. Fabry‘s dis­ease: clas­sification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963; 238: 3148– 3150.

5. Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry‘s dis­ease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276(21): 1163– 1167. doi: 10.1056/ NEJM196705252762101.

6. Kornreich R, Desnick REJ, Bishop DF. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res 1989; 17(8): 3301– 3302. doi: 10.1093/ nar/ 17.8.3301.

7. Ohshima T, Mur­ray GJ, Nagle JW et al. Structural organization and expres­sion of the mouse gene encod­­ing alpha-galactosidase. Gene 1995; 166(2): 277– 280. doi: 10.1016/ 0378-1119(95)00592-7.

8. Meikle PJ, Hopwood JJ, Clauge AE et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281(3): 249– 254. doi: 10.1001/ jama.281.3.249.

9. Spada M, Pagliardini S, Yasuda M et al. High incidence of later-onset Fabry dis­ease revealed by newborn screening. Am J Hum Genet 2006; 79(1): 31– 40. doi: 10.1086/ 504601.

10. Lin HY, Chong KW, Hsu HJ et al. High incidence of the cardiac variant of fabry dis­ease revealed by newborn screen­­ing in the taiwan Chinese population. Circ Cardiovasc Genet 2009; 2(5): 450– 456. doi: 10.1161/ CIRCGENETICS.109.862920.

11. Linthorst GE, Bouwman MG, Wijburg FA et al. Screen­­ing for Fabry dis­ease in high-risk populations: a systematic review. J Med Genet 2010; 47(4): 217– 222. doi: 10.1136/ jmg.2009.072116.

12. Rolfs A, Bottcher T, Zschiesche M et al. Prevalence of Fabry dis­ease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366(9499): 1794– 1796. doi: 10.1016/ S0140-6736(05)67635-0.

13. Brouns R, Thijs V, Eyskens F et al. Belgian Fabrystudy: prevalence of Fabry dis­ease in a cohort of 1000 young patients with cerebrovascular dis­ease. Stroke 2010; 41(5): 863– 868. doi: 10.1161/ STROKEAHA.110.579409.

14. Shi Q, Chen J, Pongmoragot J et al. Prevalence of Fabry dis­ease in stroke pa­cients –  a systematic review and meta-analysis. J Stroke Cerebrobvasc Dis 2014; 23(5): 985– 992. doi: 10.1016/ j.jstrokecerebrovasdis.2013.08.010.

15. Český statistický úřad: Obyvatelstvo. Česká republika 2017. Dostupné z URL: https: / / www.czso.cz/ csu/ czso/ obyvatelstvo_lide.

16. Merta M, Reiterová J, Ledvinová J et al. A nationwide blood spot screen­­ing study for Fabry dis­ease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 2007; 22(1): 179– 186. doi: 10.1093/ ndt/ gfl528.

17. Paleček T, Honzíková J, Poupětová H et al. Prevalence of Fabry dis­ease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screen­­ing study (FACSS). J Inherit Metab Dis 2014; 37(3): 455– 460. doi: 10.1007/ s10545-013-9659-2.

18. Ross MT, Grafham DV, Cof­fey AJ et al. The DNA sequence of the human X chromozome. Nature 2005; 434(7031): 325– 337. doi: 10.1038/ nature03440.

19. National Center for Biotechnology Information. ClinVar. Bethesda, USA: National Library of Medicine 2018. Dostupné z URL: https:/ / www.ncbi.nlm.nih.gov/ clinvar/ .

20. Aerts JM, Groener JE, Kuiper S et al. Elevated globotriaosylsphingosine is a hal­lmark of Fabry dis­ease. Proc Natl Acad Sci U S A 2008; 105(8): 2812– 2817. doi: 10.1073/ pnas.0712309105.

21. Lidove O, Ramaswai U, Jaus­saud R et al. Hyperhidrosis: a new and often early symp­tom in Fabry dis­ease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract 2006; 60(9): 1053– 1059. doi: 10.1111/ j.1742-1241.2006.01061.x

22. Kalkum G, Pitz S, Karabul N et al. Paediatric Fabry dis­ease: prognostic significance of ocular changes for dis­ease severity. BMC Ophthalmol 2016; 16(1): 202. doi: 10.1186/ s12886-016-0374-2.

23. Sims K, Politei J, Banikazemi M et al. Stroke in Fabry dis­ease frequently occurs before dia­gnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009; 40(3): 788– 794. doi: 10.1161/ STROKEAHA.108.526293.

24. Dobrovolný R, Dvořáková L, Ledvinová J et al. Relationship between X-inactivatin and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl) 2005; 83(8): 647– 654. doi: 10.1007/ s00109-005-0656-2.

25. Kolodny EH, Pastores GM. Anderson –  Fabry dis­ease: extrarenal, neurologic manifestations. J Am Soc Nephrol 2002; 13 (Suppl 2): S150– S153. doi: 10.1097/ 01.ASN.0000015239.57436.18.

26. Kahn P. Anderson –  Fabry dis­ease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry 1973; 36: 1053– 1062.

27. Politei JM, Bouhas­sira D, Germain DP et al. Pain in Fabry dis­ease: practical recom­mendations for dia­gnosis and treatment. CNS Neurosci Ther 2016; 22(7): 568– 576. doi: 10.1111/ cns.12542.

28. Hof­fmann B, Beck M, Sunder-Plas­smann G et al. Nature and prevalence of pain in Fabry dis­ease and its response to enzyme replacement ther­apy –  a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007; 23(6): 535– 542. doi: 10.1097/ AJP.0b013e318074c986.

29. Mehta A, Ricci R, Widmer U et al. Fabry dis­ease defin­ed: baseline clinical manifestation of 48366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34(3): 236– 242. doi: 10.1111/ j.1365-2362.2004.01309.x.

30. Ginsberg L. Nervous system manifestations of Fabry dis­ease: data from FOS –  the Fabry Outcome Survey. In: Mentha A, Beck M, Sunder-Plas­smann G (eds). Fabry dis­ease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis 2006: 227– 232.

31. Miners AH, Holmes A, Sherr L et al. As­ses­sment of health-related quality of life in males with Anderson Fabry Dis­ease before therapeutic intervention. Qual Life Res 2002; 11(2): 127– 133. doi: 10.1023/ A: 1015009210639.

32. Baehner F, Kampmann C, Whybra C et al. Enzyme replacement ther­apy in heterozygous females with Fabry dis­ease: results of a phase IIIB study. J Inherit Metab Cis 2003; 26(7): 617– 627. doi: 10.1023/ B: BOLI.0000005658.14563.77.

33. Cable WJ, Kolodny EH, Adams RD. Fabry dis­ease: impaired autonomic function. Neurology 1982; 32(5): 498– 502. doi: 10.1212/ WNL.32.5.498.

34. Mutoh T, Senda Y, Sugimura K. Severe orthostatic hypotension in Female a car­rier of Fabry dis­ease. Arch Neurol 1988; 45(4): 468– 472. doi: 10.1001/ archneur.1988.00520280122030.

35. O‘Mahony C, Coats C, Cardona M et al. Incidence and predictors of anti-bradycardia pac­­ing in patients with Anderson-Fabry dis­ease. Europace 2011; 13(12): 1781– 1788. doi: 10.1093/ europace/ eur267.

36. Hilz MJ, Kolodny EH, Brys M et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry dis­ease. J Neurol 2004; 251(5): 564– 570. doi: 10.1007/ s00415-004-0364-9.

37. Kaye EM, Kolodny EH, Logigian EL et al. Nervous system involvement in Fabry’s dis­ease: clinicopathological and bio­chemical cor­relation. Ann Neurol 1988; 23(5): 505– 509. doi: 10.1002/ ana.410230513.

38. Moore DF, Kaneski CR, Askari H et al. The cerebral vasculopathy of Fabry dis­ease. J Neurol Sci 2007; 257(1– 2): 258– 263. doi: 10.1016/ j.jns.2007.01.053.

39. El­leder M, Chrostomanou H, Kusterman­n-Kuhn B et al. Leptomeningeal lipid storage patterns in Fabry dis­ease. Acta Neuropathol 1994; 88(6): 579– 582. doi: 10.1007/ BF00296496.

40. Gupta S, Ries M, Kotsopoulos S et al. The relationship of vascular glycolipid storage to clinical manifestations of Fabry dis­ease: a cros­s-sectional study of a large cohort of clinical­ly af­fected heterozygous woman. Med­icine (Baltimore) 2005; 84(5): 261– 268. doi: 10.1097/ 01.md.0000178976.62537.6b.

41. Vedder AC, Linthorst GE, Van Breemen MJ et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2006; 30(1): 68– 78. doi: 10.1007/ s10545-006-0484-8.

42. Fel­lgiebel A, Kel­ler I, Martus P et al. Basilar artery diameter is a potential screen­­ing tool for Fabry dis­ease in young stroke patients. Cerebrovasc Dis 2011; 31(3): 294– 299. doi: 10.1159/ 000322558.

43. Carbera-Salazar MA, O‘Rourke E, Charia-Ortiz G et al. Radiological evidence of early cerebral microvascular dis­ease in young children with Fabry dis­ease. J Paediatr 2005; 147(1): 102– 105. doi: 10.1016/ j.jpeds.2005.03.004.

44. Rost NS, Cloonan L, Kanakis AS et al. Determinants of white matter hyperintensity burden in patients with Fabry dis­ease. Neurology 2016; 86(20): 1880– 1886. doi: 10.1212/ WNL.0000000000002673.

45. Cocozza S, Olivo G, Riccio E et al. Corpus cal­losum involvement: a useful clue for dif­ferentiat­­ing Fabry dis­ease from multiple sclerosis. Neuroradiology 2017; 59(6): 563– 570. doi: 10.1007/ s00234-017-1829-8.

46. Moore DF, Ye F, Schif­fmann R et al. Increased signal intensity in the pulvinar on T1-wighted images: A pathognomonic MR imag­­ing sign of Fabry dis­ease. AJNR Am J Neuroradiol 2003; 24(6): 1096– 1101.

47. Gavazzi C, Borsini W, Guer­rini L et al. Subcortical dam­age and cortical functional changes in men and women with Fabry dis­ease: a multifaceted MR study. Radiology 2006; 241(2): 492– 500. doi: 10.1148/ radiool.2412051122.

48. Cocozza S, Rus­so C, A. Pisani et al. Redefin­­ing the pulvinar sign in Fabry dis­ease. AJNR Am J Neuroradiol 2017; 38(12): 2264– 2269. doi: 10.3174/ ajnr.A5420.

49. Linhart A, El­liott PM. The heart in Anderson-Fabry dis­ease and other lysosomal storage disorders. Heart, 2007; 93(4): 528– 535. doi: 10.1136/ hrt.2005.063818

50. Pitz S, Kalkum G, Arash L et al. Ocular signs cor­relate well with dis­ease severity and genotype in Fabry dis­ease. PloS One 2015; 10(3): e0120814. doi: 10.1371/ journal.pone.0120814.

51. Sodi A, Ioan­nidis A, Pitz S. Ophthalmological manifestations of Fabry dis­ease. In: Mehta A, Beck M, Sunder-Plas­smann G (eds). Fabry dis­ease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis 2006.

52. Raizman MB, Hamrah P, Hol­land EJ et al. Drug-induced corneal epithelial changes. Surv Ophthalmol 2017; 62(3): 286– 301. doi: 10.1016/ j.survophthal.2016.11.008.

53. Keilmann A, Hegemann S, Conti G et al. Fabry dis­ease and the ear. In: Mehta A, Beck M, Sunder-Plas­smann G (eds). Fabry dis­ease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis 2006: 227-232.

54. Laney DA., Fernhoff PM. J Dia­gnosis of Fabry dis­ease via analysis of family history. J Genet Couns 2008; 17(1): 79-83. doi: 10.1007/ s10897-007-9128-x.

55. Eng CM, Guf­fon N, Wilcox WR et al. Safety and ef­ficacy of recombinant human alpha-galactosidase A –  replacement ther­apy in Fabry’s dis­ease. N Engl J Med 2001; 345(1): 9– 16. doi: 10.1056/ NEJM200107053450102.

56. Thurberg BL, Byers HR, Granter SR et al. Monitor­­ing the 3-year ef­ficacy of enzyme replacement ther­apy in Fabry dis­ease by repeated skin bio­psies. J Invest Dermatol 2004; 122(4): 900– 908. doi: 10.1111/ j.0022-202X.2004. 22425.x.

57. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta ther­apy for advanced Fabry dis­ease: a random­ized trial. Ann Intern Med 2007; 146(2): 77– 86. doi: 10.7326/ 0003-4819-146-2-200701160-00148.

58. Schif­fmann R, Kopp JB, Austin HA 3rd et al. Enzyme replacement ther­apy in Fabry dis­ease: a randomized control­led trial. JAMA 2001; 285(21): 2743– 2749. doi: 10.1001/ jama.285.21.2743.

59. Ortiz A, Abio­se A, Bichet DG et al. Time to treatment benefit for adult patients with Fabry dis­ease receiv­­ing agalsidase β: data from the Fabry Registry. J Med Genet 2016; 53(7): 495– 502. doi: 10.1136/ jmedgenet-2015-103486.

60. Goláň L. Migalastat v terapii Fabryho choroby. Interní Med 2017; 19(3). 167– 170.

61. Guérard N, Oder D, Nordbeck P et al. Lucerastat, an iminosugar for substrate reduction ther­apy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry Dis­ease on enzyme replacement. Clin Pharmacol Ther 2018; 103(4): 703– 711. doi: 10.1002/ cpt.790.

62. Huang J, Khan A, Au BC et al. Lentivector iterations and pre-clinical scale-up/ toxicity testing: target­­ing mobilized cd34+ cel­ls for cor­rection of Fabry dis­ease. Mol Ther Methods Clin Dev 2017; 5: 241– 258. doi: 10.1016/ j.omtm.2017.05.003.

63. Biegstraaten M, Arngríms­son R, Barbey F et al. Recom­mendations for initiation and ces­sation of enzyme replacement ther­apy in patients with Fabry dis­ease: the European Fabry Work­­ing Group consensus document. Orphane J Rare Dis 2015; 10: 36. doi: 10.1186/ s13023-015-0253-6.

Štítky
Dětská neurologie Neurochirurgie Neurologie
Článek Editorial
Článek Ataxie

Článek vyšel v časopise

Česká a slovenská neurologie a neurochirurgie

Číslo 2

2018 Číslo 2

Nejčtenější v tomto čísle
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#